A Cochrane review [Abstract] 1 included 4 RCTs with a total of 236 patients with epilepsy. Only one study reported 50% or greater reduction in seizure frequency. One study reported absolute and percentage reduction in seizure frequency compared to placebo, P values were 0.046 and 0.018, respectively. One study reported percentage reduction in seizure frequency compared to placebo, but there were no P values. Adverse effects rates were higher during the felbamate period than the placebo period, particularly headache, nausea and dizziness.
Comment: The quality of the evidence is downgraded by study quality (unclear allocation concealment), inconsistency (heterogeneity in interventions and outcomes), indirectness of evidence (differences in outcomes) and imprecise results (limited study size for each comparison).
Primary/Secondary Keywords